Clarient to Present at Upcoming Healthcare Investor Conferences in New York City
* Reuters is not responsible for the content in this press release.
ALISO VIEJO, Calif., Nov. 9 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq:
CLRT), a premier technology and services resource for pathologists,
oncologists and the pharmaceutical industry, today announced that it is
scheduled to make presentations at two upcoming investor conferences in New
York City.
The first presentation will be made at the Lazard Capital Markets Sixth Annual
Healthcare Conference at 1:40 pm EST on Tuesday, November 17. The conference
will be held at the St. Regis Hotel November 17-18.
The second presentation will be made at the 21st Annual Piper Jaffray Health
Care Conference at 10:30 am EST on Wednesday, December 2. The conference will
be held at the New York Palace Hotel December 1-2.
Live webcasts of the Company's presentations at the conferences will be
available via a link provided at http://www.clarientinc.com/investor.
Archived replays of the presentations will also be available shortly after the
presentation time for a period of at least 60 days.
About Clarient
Clarient combines innovative diagnostic technologies with world-class
pathology expertise to assess and characterize cancer. Clarient's mission is
to become the leader in cancer diagnostics by collaborating with the
healthcare community to translate cancer research and development into better
patient care. Clarient's principal customers include pathologists,
oncologists, hospitals and biopharmaceutical companies. The rise of
individualized medicine has created the need for a centralized resource which
provides leading oncology diagnostic technologies, such as flow cytometry and
molecular testing. Clarient is that resource, having created a
state-of-the-art commercial cancer laboratory, which provides the most
advanced oncology testing and diagnostic services available. Resulting
diagnostic reports and analyses are made available to customers through
Clarient's Internet-based portal, PATHSiTE(TM). Clarient also plans to
develop and market new, proprietary "companion" diagnostic markers for
therapeutics in breast, prostate, lung and colon cancers, and
leukemia/lymphoma. www.clarientinc.com
Investor Contact:
Matt Clawson
Allen & Caron Inc
(949) 474-4300
matt@allencaron.com
SOURCE Clarient, Inc.
Investors, Matt Clawson of Allen & Caron Inc, +1-949-474-4300,
matt@allencaron.com, for Clarient, Inc.
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters